Gene · 7468
Papers2,351
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 2,351
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| New Insights into Potential Therapeutic Targets for Neuroendocrine Prostate Cancer: From Bench to Clinic. | Research (Wash D C) | 2025 | 40746825 | PubTator, text mining | PubMed |
| Epigenetic regulation of cancer stemness. | Signal Transduct Target Ther | 2025 | 40744921 | PubTator, text mining | PubMed |
| Ferroptosis: a novel pharmacological mechanism against multiple myeloma. | Front Pharmacol | 2025 | 40735482 | PubTator, text mining | PubMed |
| Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs. | Commun Chem | 2025 | 40730655 | PubTator, text mining | PubMed |
| NSD2 promotes cell durotaxis and drives the transition from polycystic kidney disease to tubulocystic renal cell carcinoma through integrin/FAK/AKT signaling. | Oncogene | 2025 | 40696168 | PubTator, text mining | PubMed |
| Unveiling the Role of Histone Methyltransferases in Psoriasis Pathogenesis: Insights from Transcriptomic Analysis. | Int J Mol Sci | 2025 | 40650108 | PubTator, text mining | PubMed |
| Characterization of the activity of KTX-1001, a small molecule inhibitor of multiple myeloma SET domain using surface plasmon resonance. | J Biol Chem | 2025 | 40523621 | PubTator, text mining | PubMed |
| A phase II, multicenter, single-arm study of pemigatinib in patients with metastatic or unresectable colorectal cancer harboring FGFR alterations. | Oncologist | 2025 | 40515475 | PubTator, text mining | PubMed |
| The H3 K36M oncohistone inhibits NSD2 to activate a SETD2-dependent antiviral-like immune response in KRAS-driven lung cancer. | bioRxiv | 2025 | 40501771 | PubTator, text mining | PubMed |
| NSD2 and miRNAs as Key Regulators of Melanoma Response to Romidepsin and Interferon-α2b Treatment. | Cancer Med | 2025 | 40386826 | PubTator, text mining | PubMed |
| Investigating additional malignancy rates and prognostic factors in multiple myeloma patients: a Surveillance, Epidemiology, and End Results (SEER) database retrospective cohort study. | Transl Cancer Res | 2025 | 40386261 | PubTator, text mining | PubMed |
| Prognostic and diagnostic value of PVR gene and protein levels, serum amylase, and urinary IGFBP-7 and TIMP-2 biomarkers in multiple myeloma. | BMC Cancer | 2025 | 40369504 | PubTator, text mining | PubMed |
| Nuclear Receptor-Binding SU(VAR)3-9, Enhancer of Zeste, Trithorax Domain Structural Domain Protein 2 Serves as a Potential Prognostic Biomarker in Mantle Cell Lymphoma. | Lab Invest | 2025 | 40306573 | PubTator, text mining | PubMed |
| Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma. | Ann Hematol | 2025 | 40278919 | PubTator, text mining | PubMed |
| Epigenetics of maternal-fetal interface immune microenvironment and placental related pregnancy complications. | Front Immunol | 2025 | 40248704 | PubTator, text mining | PubMed |
| NUP62 alleviates senescence and promotes the stemness of human dental pulp stem cells via NSD2-dependent epigenetic reprogramming. | Int J Oral Sci | 2025 | 40246825 | PubTator, text mining | PubMed |
| Integrated Network Pharmacology, Molecular Modeling, LC-MS Profiling, and Semisynthetic Approach for the Roots of Rubia tinctorum L. Metabolites in Cancer Treatment. | ACS Omega | 2025 | 40224436 | PubTator, text mining | PubMed |
| Molecular Characteristics of Prognosis and Chemotherapy Response in Breast Cancer: Biomarker Identification Based on Gene Mutations and Pathway. | J Breast Cancer | 2025 | 40133984 | PubTator, text mining | PubMed |
| NSD2-epigenomic reprogramming and maintenance of plasma cell phenotype in t(4;14) myeloma. | Oncotarget | 2025 | 40116454 | PubTator, text mining | PubMed |
| H3K36me2 methyltransferase NSD2/WHSC1 promotes triple-negative breast cancer metastasis via activation of ULK1-dependent autophagy. | Autophagy | 2025 | 40097917 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7468/papers?page=5